What is SentiAR?
Established in 2017 and headquartered in Missouri, SentiAR is pioneering the application of Mixed Reality technology within the healthcare sector. The company's flagship platform is designed to provide clinicians with an immersive command center during interventional procedures, beginning with cardiac ablation for conditions like atrial fibrillation. By presenting a real-time, 3D hologram of patient electro-anatomic data, SentiAR aims to revolutionize how complex medical interventions are performed, potentially improving patient outcomes and procedural efficiency. The company's focus on integrating advanced visualization into critical medical workflows positions it at the forefront of MedTech innovation.
How much funding has SentiAR raised?
SentiAR has raised a total of $16.3M across 4 funding rounds:
Angel/Seed
$1.1M
Debt
$144K
Series A
$5.1M
Series B
$8.5M
Angel/Seed (2017): $1.1M, investors not publicly disclosed
Debt (2021): $144K led by PPP
Series A (2021): $5.1M supported by Keiretsu Forum, Neue Fund, VCapital, QRM Capital, BioGenerator Company, Cultivation Capital, and TechWald Holding S.p.A
Series B (2023): $8.5M featuring TechWald Holding SpA, VCapital, and MedVenture Partners
Key Investors in SentiAR
TechWald Holding SpA
TechWald Holding S.p.A. is an operational holding company that invests in early-stage companies focused on healthcare innovation, particularly in the MedTech industry. Their portfolio includes medical devices, equipment, and digital services aimed at benefiting patients, doctors, and healthcare systems.
VCapital
VCapital is a Chicago-based venture capital firm focused on early-stage companies. Their strategy is to invest in companies that offer the ability for exceptional, profitable growth. Their investments span medical device, biotechnology, technology, telecommunications and more.
MedVenture Partners
MedVenture Partners is an independent company providing Corporate Finance and Strategy Advisory Services focused on the life science and health care industries and their investors. The core of our solutions is the integration of managerial and consulting methodologies with health economic evaluation techniques.
What's next for SentiAR?
The recent substantial investment, characterized as a major strategic financing, signals SentiAR's transition into a scaling phase. This capital injection is expected to accelerate product development, expand market reach, and further solidify its technological advantage in the competitive MedTech landscape. SentiAR's commitment to advancing interventional cardiology through Mixed Reality suggests a strategic focus on partnerships and clinical validation to drive adoption. Future growth will likely involve expanding the platform's capabilities to other interventional specialties and enhancing its integration with existing healthcare IT infrastructure.
See full SentiAR company page
